Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAX 802 perioperative hemostasis study in congenital hemophilia A with inhibitors
NL-OMON47364Phase 3Active, not recruiting
- Sponsor
- Baxter International Inc.
- Start
- Dec 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of susoctocog alfa in hemophilia A, sponsored by Baxter International Inc. Primary endpoint: Proportion of procedures with good or excellent hemostatic response by GHEA score. Started Dec 2016; status: active, not recruiting.
02
Drugs
susoctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NL-OMON47364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47364.